Liquidia (NASDAQ:LQDA) General Counsel Russell Schundler Sells 27,289 Shares

Liquidia Corporation (NASDAQ:LQDA) General Counsel Russell Schundler sold 27,289 shares of Liquidia stock in a transaction dated Monday, January 12th. The shares were sold at an average price of $37.43, for a total value of $1,021,427.27. Following the completion of the transaction, the general counsel directly owned 579,394 shares in the company, valued at $21,686,717.42. This represents a 4.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Russell Schundler also recently made the following trade(s):

• On Monday, December 1st, Russell Schundler sold 1,072 shares of Liquidia stock. The shares were sold at an average price of $32.19, for a total transaction of $34,507.68.

Liquidia Price Performance

LQDA opened at $38.09 on Wednesday. The company has a 50 day moving average of $32.14 and a two-hundred day moving average of $25.58. Liquidia Corporation has a 52-week low of $11.26 and a 52-week high of $39.29. The company has a quick ratio of 1.96, a current ratio of 2.20 and a debt-to-equity ratio of 6.19. The company has a market cap of $3.31 billion, a P/E ratio of -26.45, a P/E/G ratio of 1.22 and a beta of 0.48.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings results on Monday, November 3rd. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.41. Liquidia had a negative net margin of 176.04% and a negative return on equity of 296.78%. The firm had revenue of $54.34 million during the quarter, compared to analysts’ expectations of $18.86 million. Liquidia’s revenue for the quarter was up 1106.7% on a year-over-year basis. On average, analysts expect that Liquidia Corporation will post -1.51 earnings per share for the current year.

Liquidia News Summary

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Short interest fell materially in December — short interest declined about 18.1% to ~10.71M shares as of Dec. 31 (about 17.6% of shares outstanding), lowering potential downward pressure from short sellers and reducing immediate squeeze risk.
• Neutral Sentiment: Reported short-interest data for Jan. 12 appears inconsistent (shows 0 shares / NaN change), which looks like a reporting glitch and should be treated as unreliable until corrected.
• Negative Sentiment: CEO Roger Jeffs sold 66,610 shares at an average of $37.43 for roughly $2.49M, reducing his direct stake by ~6.0%. SEC Filing – Roger Jeffs
• Negative Sentiment: CFO Michael Kaseta sold 36,932 shares at $37.43 for about $1.38M, a ~9.5% reduction in his holding. SEC Filing – Michael Kaseta
• Negative Sentiment: General Counsel Russell Schundler sold 27,289 shares at $37.43 for about $1.02M, a ~4.5% stake reduction. SEC Filing – Russell Schundler
• Negative Sentiment: Insider Rajeev Saggar sold 21,142 shares at $37.43 (~$791k), cutting his holdings by ~10.7%. SEC Filing – Rajeev Saggar
• Negative Sentiment: Scott Moomaw sold 20,533 shares at $37.43 (~$769k), an ~11.7% reduction in his stake. SEC Filing – Scott Moomaw
• Negative Sentiment: CAO Dana Boyle sold 11,047 shares at $37.43 (~$413k), a ~6.6% reduction. SEC Filing – Dana Boyle
• Negative Sentiment: Insider Jason Adair sold 13,548 shares at $37.43 (~$507k), and Sarah Krepp sold 13,165 shares (~$493k); both reduced holdings by mid-single-digit to high-single-digit percentages. SEC Filing – Jason Adair SEC Filing – Sarah Krepp

Hedge Funds Weigh In On Liquidia

Large investors have recently added to or reduced their stakes in the company. Farallon Capital Management LLC raised its holdings in shares of Liquidia by 102.1% during the third quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock worth $194,783,000 after purchasing an additional 4,326,876 shares during the period. Vanguard Group Inc. raised its stake in Liquidia by 10.2% during the third quarter. Vanguard Group Inc. now owns 3,961,217 shares of the company’s stock worth $90,078,000 after acquiring an additional 367,659 shares during the period. Opaleye Management Inc. raised its stake in Liquidia by 9.5% during the second quarter. Opaleye Management Inc. now owns 2,475,000 shares of the company’s stock worth $30,838,000 after acquiring an additional 215,000 shares during the period. TCG Crossover Management LLC bought a new position in Liquidia in the third quarter worth about $38,887,000. Finally, Caprock Group LLC acquired a new position in Liquidia in the third quarter valued at approximately $37,114,000. 64.54% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

LQDA has been the subject of several analyst reports. Wall Street Zen upgraded shares of Liquidia from a “hold” rating to a “buy” rating in a research note on Saturday. Wells Fargo & Company assumed coverage on Liquidia in a research note on Monday, October 20th. They set an “overweight” rating and a $31.00 target price for the company. Needham & Company LLC boosted their price target on Liquidia from $36.00 to $52.00 and gave the stock a “buy” rating in a research note on Tuesday, November 4th. Jefferies Financial Group raised their price objective on Liquidia from $45.00 to $55.00 and gave the company a “buy” rating in a research note on Tuesday. Finally, HC Wainwright upped their target price on Liquidia from $35.00 to $50.00 and gave the company a “buy” rating in a research report on Tuesday, November 4th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Liquidia currently has a consensus rating of “Moderate Buy” and a consensus target price of $39.67.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).